These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38972151)

  • 1. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.
    Zhang G; Li J; Li G; Zhang J; Yang Z; Yang L; Jiang S; Wang J
    Clin Exp Med; 2024 Aug; 24(1):193. PubMed ID: 39141161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
    Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
    Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
    Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
    Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.
    Vick SC; Kolupaev OV; Perou CM; Serody JS
    J Immunol; 2021 Nov; 207(10):2598-2607. PubMed ID: 34607937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.